Medartis announced that its CEO, Christoph Brönnimann, has decided to resign from his position and leave the company to pursue other opportunities.
Brönnimann will continue to lead Medartis until a successor is on board. He will remain focused on the execution of the company’s strategy and committed to a smooth transition to the new leadership, according to a news release from Medartis. The board has initiated a search for his successor and will announce an appointment in due course.
Medartis Chairman Marco Gadola said, “Under Christoph’s leadership, Medartis has significantly accelerated its growth in its key markets, broadened the product portfolio and strengthened its standing with leading surgeons and hospitals worldwide. He has also expanded the capabilities of the organization and fostered an engaging culture, positioning the company for future success. This work will continue and growth remains our top priority.”
Brönnimann said, “While this has been a difficult decision for me, I am proud of what we have accomplished together over the past five years. I will leave behind a talented executive team, a passionate organization and a company with huge potential for future growth.”
The Board of Directors thanked Brönnimann for his leadership, valuable contributions to Medartis and its success during his tenure, and wishes him all the best for his future endeavors, the release states.
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and suppliers of medical devices for the surgical fixation of bone fractures in the upper and lower extremities and the craniomaxillofacial region. Medartis employs more than 830 people in 13 locations and its products are sold in more than 50 countries worldwide. Medartis is committed to providing surgeons and surgical staff with the most innovative titanium implants and instruments, as well as world-class service, the release states. For more information, visit www.medartis.com.